Australian Stock Report - Share Tips
ASX Health Care Stocks News: ResMed (RMD)
share-tips
Publish date: Tue, 25 Oct 2011, 03:17 PM
share-tips
0 1,810
Our stock analysis blog provides information on stocks to watch and helps you figure out which are the best stock to buy. We use fundamental and technical analysis to identify the stocks tips that will supercharge your portfolio. We don't believe in choosing stock tips on rumours or hearsay. Our share tips use fundamental analysis, like price-to-equity ratios, cash flow analysis and net tangible assets, to identify the best share trading opportunities. We then use technical analysis, which is the study of price charts, to determine the best level to buy shares. We believe using the two school of investment analysis allows us the increase the chances of our share tips being successful.
ResMed (ASX:RMD) is a leading developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders such as sleep apnoea.
Today RMD announced a 12% increase in 1Q11 revenue to $314.8 million. However net profit was down 11% to $50.5 million.
Although the result was affected by adverse exchange rate movements, RMD was also hit by a weak 1% increase in flow generator sales.
The sales result missed analyst estimates, causing it to become the worst performer in today's share market action.
Receive FREE Trading Recommendations for the next 7 Days, Click Here!
ASX Health Care Stocks News: ResMed (RMD) is a post from: Australian Stock Report Share Tips
Related posts:
- ASX Stocks to Watch Alesco Corporation (ALS)
- Industrial Stocks News Downer EDI (DOW)
- Best Stocks News: Newcrest Mining (NCM)
Related Stocks
| Chart | Stock Name | Last | Change | Volume |
|---|
Market Buzz
More articles on Australian Stock Report - Share Tips
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Apps
Top Articles
1
2
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
